Oncolytic virus injection for advanced solid tumors
Part of Brain & nervous system, Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor diagnosis confirmed by biopsy (histology) or body-fluid sample (cytology)
- Your cancer has not responded to standard treatment, or you don’t want other cancer treatments
- You are between 18 and 75 years old, and your expected survival is at least 3 months
- You have at least one tumor spot that can be reached by injection into the tumor or into the belly (abdomen)
- Your blood and organ tests must be within set limits (including blood counts and liver/kidney function)
- You must be willing to use effective birth control during the study and for 180 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational virus therapy (R130) injected directly into tumors for people with advanced bone or soft tissue cancer who have exhausted standard treatments or choose not to pursue them.
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
This trial tests an experimental virus therapy called VSV-02 for people with advanced solid tumors that have not responded to standard treatments. The treatment is given directly into a tumor, aiming to attack cancer from the inside.
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.